ArticleAnnals of surgical oncology2026
Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tanshinone IIA inhibits malignant progression in a spontaneous breast cancer mouse model by attenuating tissue factor-mediated angiogenesis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTissue factor (TF), a key initiator of the coagulation cascade, is frequently overexpressed in pancreatic cancer and linked to tumor progression and thrombosis. While TF has been recognized as a prognostic biomarker, its clinical relevance in surgically treated patients remains unclear.
methodsWe retrospectively analyzed TF expression in resected pancreatic cancer specimens from 265 patients, including those with and without preoperative therapy, using immunohistochemistry. Tissue factor expression was semiquantitatively classified as negative, low, or high. Associations with clinicopathological features, treatment response, and survival were evaluated.
resultsHigh TF expression was observed in 17.4% of cases and was significantly associated with elevated CA19-9, biologically borderline resectable disease, and lymph node metastases. These patients had shorter overall survival (median overall survival: 20.6 vs. 38.8 vs. 53.6 months, p < 0.001). High TF expression remained an independent predictor of poor prognosis (hazard ratio [HR]: 2.21, p = 0.0002). Tissue factor-negative tumors were associated with favorable outcomes, including long-term survival despite recurrence. Tissue factor expression decreased following preoperative therapy but did not correlate with histological response.
conclusionsTissue factor expression stratifies pancreatic cancer into biologically and prognostically distinct subgroups. While high TF expression indicates aggressive disease and poor survival, TF-negative tumors represent an indolent, treatment-sensitive subtype. These findings underscore the biological heterogeneity of pancreatic cancer and support TF as a clinically relevant prognostic biomarker.
Indexed as
Identifiers
41817932What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.